Skip to main content
IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NameAducanumabCAS Registry Number 1384260-65-4

Physical Data

No data available

Spectra

No data available

Route of Synthesis (ROS)

No data available

Safety and Hazards

No data available

Other Data

No data available

Use PatternAducanumab CAS#: 1384260-65-4 is a human monoclonal antibody and is the first and only Alzheimer's disease treatment to address the clear pathology of the disease by reducing amyloid plaques in the brain. ADUHELM™ is indicated for the treatment of Alzheimer's disease. This indication was granted under accelerated approval for amyloid plaque reduction in patients treated with ADUHELM™.
https://www.chemwhat.com/aducanumab-cas-1384260-65-4/

Comments

Post a Comment

Popular posts from this blog

BCB (Benzocyclobutene): — Watson International Enables the Transition from Concept to Scalable Application

Benzocyclobutene (BCB) is an organic compound with a rigid molecular structure composed of a conjugated benzene ring and a four-membered ring. Its excellent thermal stability and electrical properties have made it a highly promising candidate for next-generation electronic materials. Historically, its industrial adoption has been constrained by high production costs, complex purification processes, and limited output. However, with growing demand in high-end applications and recent advances in upstream technology, BCB is now poised for industrial-scale deployment. Material Properties and Structural Advantages BCB (C₈H₈) is a non-polar molecule, free of ester, carboxyl, or amide groups, giving it excellent dielectric properties and low moisture absorption. Its dielectric constant (Dk) and dissipation factor (Df) remain stable across wide temperature and frequency ranges—key metrics for ensuring signal integrity in high-frequency, high-speed communication systems. Unlike conventional m...
Post a Comment
Read more

BCB (Benzocyclobutene): — Watson International Enables the Transition from Concept to Scalable Application

Despite BCB’s well-established performance advantages, its commercialization has long been hindered by production cost and scalability challenges. Watson International has made critical breakthroughs in BCB industrialization through integrated innovation in synthesis, purification, and material formulation: Cost Reduction: By optimizing synthetic pathways and improving by-product recovery, Watson has significantly reduced the unit production cost of BCB, enabling cost-effective scaling; High Purity Production: Advanced purification and process control technologies ensure high-purity BCB under mass-production conditions—meeting stringent requirements from high-end electronic manufacturers; Versatile Co-polymerization: Watson’s BCB materials are compatible with other advanced resins such as BMI and PPO, allowing for custom co-polymer design and performance tuning.
Post a Comment
Read more

The World's Largest Producer of Squaric Acid Emerges: Watson Leads the Way

In a groundbreaking development for the chemical industry, Watson has officially claimed the title of the world’s largest producer of squaric acid. This achievement marks a significant milestone, positioning the company as a global leader in the production of this highly versatile compound, widely valued in pharmaceuticals, polymer research, and advanced materials. What is Squaric Acid? Squaric acid, also known as quadratic acid, is a four-carbon cyclic diketone with two ketone groups and two hydroxyl groups arranged symmetrically. It is renowned for its stability and strong acidity, making it a unique compound in both organic and inorganic chemistry. Its derivatives find applications in creating advanced coatings, conductive polymers, and as intermediates in drug synthesis. Watson: Redefining Excellence in Squaric Acid Production Watson’s rise to the top of the squaric acid industry is backed by its unmatched production capacity, cutting-edge technology, and unwavering commitment...
Post a Comment
Read more